8-K: BioCardia Announces 1-for-15 Reverse Stock Split to Regain Nasdaq Compliance

BioCardia, Inc. will implement a 1-for-15 reverse stock split effective May 30, 2024, to increase its stock price and maintain its Nasdaq listing.

Summary

• BioCardia held its Annual Meeting on May 20, 2024, where several proposals were voted on by shareholders.
• The company's board of directors was re-elected, and the appointment of PKF San Diego, LLP as the independent auditor was ratified.
• Executive compensation was approved on an advisory basis.
• A proposal to enact a reverse stock split at a ratio between 1-for-2 and 1-for-20, to be determined by the board, was approved.
• The company has decided on a 1-for-15 reverse stock split, effective May 30, 2024.
• The reverse stock split is intended to increase the company's stock price to meet Nasdaq's minimum bid price requirement.
• Following the reverse stock split, the number of authorized shares will be reduced from 100,000,000 to 50,000,000.
• Fractional shares resulting from the split will be paid out in cash based on the closing price on May 29, 2024.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the need for a reverse stock split, which is often a sign of financial distress and a struggling stock price. While the company is taking action to maintain its listing, the underlying issues remain a concern.

Positives

• The reverse stock split is a proactive measure to maintain the company's listing on the Nasdaq Capital Market.
• Shareholders holding shares electronically will have their positions automatically adjusted.
• The company is providing clear instructions for shareholders holding physical stock certificates.
• The company is addressing the issue of fractional shares by providing cash payments.

Negatives

• The company cannot guarantee that the stock price will reflect the split ratio or remain above the pre-split trading price.
• The reverse stock split may be perceived negatively by some investors.
• The company's stock price has been below the Nasdaq minimum bid price requirement, necessitating the reverse stock split.

Risks

• The company's stock price may not increase as intended after the reverse stock split.
• The company's ability to raise additional funds and advance clinical trials remains a risk.
• The company's liquidity position is a concern.
• There is no guarantee that the company will maintain compliance with Nasdaq listing requirements.

Future Outlook

The company intends to regain compliance with Nasdaq's minimum bid price requirement through the reverse stock split, but there is no guarantee of success. The company's future performance is subject to risks related to liquidity, funding, and clinical trial advancements.

Management Comments

• The reverse stock split is intended to increase the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
• The company cannot assure that the price of its common stock after the reverse stock split will reflect the corresponding split ratio.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low stock prices. This action is often seen in the biotech sector where companies may experience volatility due to the nature of their research and development.

Comparison to Industry Standards

• Many biotech companies facing similar listing challenges have implemented reverse stock splits, such as Athersys which recently completed a 1-for-25 reverse stock split.
• The 1-for-15 ratio is within the typical range for reverse stock splits, which can vary from 1-for-2 to 1-for-25 or even higher.
• The reduction in authorized shares is a common practice to maintain a reasonable number of shares outstanding after a reverse split, similar to what other companies like Ocugen have done.

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own, but their percentage ownership will remain the same, except for fractional shares.
• The reverse stock split may impact the perceived value of the company by investors.
• The company's ability to maintain its Nasdaq listing is crucial for investor confidence.

Next Steps

• The reverse stock split will become effective on May 30, 2024.
• The company's stock will begin trading on a split-adjusted basis on May 30, 2024.
• Stockholders holding physical certificates will receive instructions from the transfer agent.

Key Dates

Keywords

reverse stock split, Nasdaq, stock price, shareholders, common stock, BioCardia, listing, compliance, authorized shares, annual meeting